Insulet Corp. (PODD) Interest Expense
The interest expense for Insulet Corp. (PODD) is $79.70 Million with a year-over-year change of +86.65%. Interest expense is the cost a company incurs for borrowed funds, including interest on bonds, loans, and other forms of debt financing.
PODD Interest Expense Chart
Reported annual fiscal-period values; no daily interpolation.
Current Interest Expense
$79.70M
$79.70 Million
Year-over-Year Change
+86.65%
vs. $42.70M prior year
Historical Data
24
Years of data available
Annual Interest Expense History
| Year | Interest Expense | YoY Change | % Change |
|---|---|---|---|
| 2025 | $79.70M | +$37.00M | +86.65% |
| 2024 | $42.70M | +$6.50M | +17.96% |
| 2023 | $36.20M | +$200,000 | +0.56% |
| 2022 | $36.00M | $-25.70M | -41.65% |
| 2021 | $61.70M | +$13.60M | +28.27% |
| 2020 | $48.10M | +$13.50M | +39.02% |
| 2019 | $34.60M | +$12.40M | +55.88% |
| 2018 | $22.20M | +$3.01M | +15.69% |
| 2017 | $19.19M | +$4.80M | +33.35% |
| 2016 | $14.39M | +$1.68M | +13.18% |
| 2015 | $12.71M | $-1.98M | -13.45% |
| 2014 | $14.69M | $-2.20M | -13.04% |
| 2013 | $16.89M | +$1.09M | +6.93% |
| 2012 | $15.79M | +$1.08M | +7.33% |
| 2011 | $14.71M | $-7.98M | -35.16% |
| 2010 | $22.69M | +$2.51M | +12.45% |
| 2009 | $20.18M | +$12.96M | +179.37% |
| 2008 | $7.22M | +$7.22M | — |
| 2007 | $0 | +$0 | — |
| 2006 | $0 | +$0 | — |
| 2005 | $0 | +$0 | — |
| 2004 | $0 | +$0 | — |
| 2003 | $0 | +$0 | — |
| 2002 | $0 | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy